Effects of artemisinin antimalarials on Cytochrome P450 enzymes in vitro using recombinant enzymes and human liver microsomes: potential implications for combination therapies

References

• Alin MH, Ashton M, Kihamia CM, et al. (1996). Clinical efficacy and pharmacokinetics of artemisinin monotherapy and in combination with mefloquine in patients with falciparum malaria. Br J Clin Pharmacol 41:587–92
   PubMedGoogle Scholar
• Ashton M, Hai TN, Sy ND, et al. (1998a). Artemisinin pharmacokinetics is time-dependent during repeated oral administration in healthy male adults. Drug Metab Dispos Biol Fate Chem 26:25–7
   PubMed Web of Science ®Google Scholar
• Ashton M, Nguyen DS, Nguyen VH, et al. (1998b). Artemisinin kinetics and dynamics during oral and rectal treatment of uncomplicated malaria. Clin Pharmacol Ther 63:482–93
   PubMedGoogle Scholar
• Asimus S, Elsherbiny D, Hai TN, et al. (2007). Artemisinin antimalarials moderately affect cytochrome P450 enzyme activity in healthy subjects. Fundam Clin Pharmacol 21:307–16
   PubMed Web of Science ®Google Scholar
• Atkins WM. (2005). Non-Michaelis–Menten kinetics in cytochrome P450-catalyzed reactions. Annu Rev Pharmacol Toxicol 45:291–310
   PubMed Web of Science ®Google Scholar
• Augustijns P, D'Hulst A, Van Daele J, Kinget R. (1996). Transport of artemisinin and sodium artesunate in Caco-2 intestinal epithelial cells. J Pharm Sci 85:577–9
   PubMed Web of Science ®Google Scholar
• Backonja MM, Irving G, Argoff C. (2006). Rational multidrug therapy in the treatment of neuropathic pain. Curr Pain Headache Rep 10:34–8
   PubMedGoogle Scholar
• Bapiro TE, Egnell AC, Hasler JA, Masimirembwa CM. (2001). Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450s. Drug Metab Dispos Biol Fate Chem 29:30–5
   PubMed Web of Science ®Google Scholar
• Bapiro TE, Sayi J, Hasler JA, et al. (2005). Artemisinin and thiabendazole are potent inhibitors of cytochrome P450 1A2 (CYP1A2) activity in humans. Eur J Clin Pharmacol 61:755–61
   PubMed Web of Science ®Google Scholar
• Batty KT, Ilett KF, Davis TM. (2004). Protein binding and alpha: beta anomer ratio of dihydroartemisinin in vivo. Br J Clin Pharmacol 57:529–33
   PubMedGoogle Scholar
• Chauret N, Gauthier A, Nicoll-Griffith DA. (1998). Effect of common organic solvents on in vitro cytochrome P450-mediated metabolic activities in human liver microsomes. Drug Metab Dispos Biol Fate Chem 26:1–4
   PubMed Web of Science ®Google Scholar
• Colussi D, Parisot C, Legay F, Lefevre G. (1999). Binding of artemether and lumefantrine to plasma proteins and erythrocytes. Eur J Pharm Sci Official J Eur Federation Pharm Sci 9:9–16
   PubMed Web of Science ®Google Scholar
• Elsherbiny DA, Asimus SA, Karlsson MO, et al. (2008). A model based assessment of the CYP2B6 and CYP2C19 inductive properties by artemisinin antimalarials: implications for combination regimens. J Pharm Pharmacodyn 35:203–17
   PubMed Web of Science ®Google Scholar
• Ericsson T, Masimirembwa C, Abelo A, Ashton M. (2012). The evaluation of CYP2B6 inhibition by artemisinin antimalarials in recombinant enzymes and human liver microsomes. Drug Metab Lett 6:247–57
   PubMedGoogle Scholar
• Ezzet F, Mull R, Karbwang J. (1998). Population pharmacokinetics and therapeutic response of CGP 56697 (artemether + benflumetol) in malaria patients. Br J Clin Pharmacol 46:553–61
   PubMed Web of Science ®Google Scholar
• FDA (US Food and Drug Administration). (2012). Guidance for industry: drug interaction studies – study design, data analysis, implications for dosing, and labeling recommendations. Silver Spring (MD): US Food and Drug Administration, Center for Drug Evaluation and Research (CDER)
   Google Scholar
• Gordi T, Huong DX, Hai TN, et al. (2002). Artemisinin pharmacokinetics and efficacy in uncomplicated-malaria patients treated with two different dosage regimens. Antimicrob Agents Chemother 46:1026--31
   PubMed Web of Science ®Google Scholar
• He F, Bi HC, Xie ZY, et al. (2007). Rapid determination of six metabolites from multiple cytochrome P450 probe substrates in human liver microsome by liquid chromatography/mass spectrometry: application to high-throughput inhibition screening of terpenoids. Rapid Commun Mass Spectrom 21:635–43
   PubMed Web of Science ®Google Scholar
• Ito K, Brown HS, Houston JB. (2004). Database analyses for the prediction of in vivo drug–drug interactions from in vitro data. Br J Clin Pharmacol 57:473–86
   PubMed Web of Science ®Google Scholar
• Ito K, Iwatsubo T, Kanamitsu S, et al. (1998). Quantitative prediction of in vivo drug clearance and drug interactions from in vitro data on metabolism, together with binding and transport. Annu Rev Pharmacol Toxicol 38:461–99
   PubMed Web of Science ®Google Scholar
• Kanamitsu S, Ito K, Sugiyama Y. (2000). Quantitative prediction of in vivo drug–drug interactions from in vitro data based on physiological pharmacokinetics: use of maximum unbound concentration of inhibitor at the inlet to the liver. Pharm Res 17:336–43
   PubMed Web of Science ®Google Scholar
• Kim MJ, Kim H, Cha IJ, et al. (2005). High-throughput screening of inhibitory potential of nine cytochrome P450 enzymes in vitro using liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 19:2651–8
   PubMed Web of Science ®Google Scholar
• Mihara K, Svensson US, Tybring G, et al. (1999). Stereospecific analysis of omeprazole supports artemisinin as a potent inducer of CYP2C19. Fundam Clin Pharmacol 13:671–5
   PubMed Web of Science ®Google Scholar
• Na-Bangchang K, Krudsood S, Silachamroon U, et al. (2004). The pharmacokinetics of oral dihydroartemisinin and artesunate in healthy Thai volunteers. Southeast Asian J Trop Med Public Health 35:575–82
   PubMedGoogle Scholar
• Pelkonen O, Turpeinen M, Hakkola J, et al. (2008). Inhibition and induction of human cytochrome P450 enzymes: current status. Arch Toxicol 82:667–715
   PubMed Web of Science ®Google Scholar
• Perdaems N, Blasco H, Vinson C, et al. (2010). Predictions of metabolic drug–drug interactions using physiologically based modelling: two cytochrome P450 3A4 substrates coadministered with ketoconazole or verapamil. Clin Pharmacokinet 49:239–58
   PubMed Web of Science ®Google Scholar
• Shou M, Lin Y, Lu P, et al. (2001). Enzyme kinetics of cytochrome P450-mediated reactions. Curr Drug Metab 2:17–36
   PubMed Web of Science ®Google Scholar
• Sidhu JS, Ashton M, Huong NV, et al. (1998). Artemisinin population pharmacokinetics in children and adults with uncomplicated falciparum malaria. Br J Clin Pharmacol 45:347–54
   PubMed Web of Science ®Google Scholar
• Simonsson US, Jansson B, Hai TN, et al. (2003). Artemisinin autoinduction is caused by involvement of cytochrome P450 2B6 but not 2C9. Clin Pharmacol Ther 74:32–43
   PubMed Web of Science ®Google Scholar
• Stresser DM. (2004). High-throughput screening of human cytochrome P450 inhibitors using fluorometric substrates. In: Yan Z, Caldwell GW, eds. Optimization in drug-discovery – in vitro methods. Spring House (PA): Johnson & Johnson Pharmaceutical Research & Development, 215–30
   Google Scholar
• Stresser DM, Blanchard AP, Turner SD, et al. (2000). Substrate-dependent modulation of CYP3A4 catalytic activity: analysis of 27 test compounds with four fluorometric substrates. Drug Metab Dispos Biol Fate Chem 28:1440–8
   PubMed Web of Science ®Google Scholar
• Svensson US, Ashton M, Trinh NH, et al. (1998). Artemisinin induces omeprazole metabolism in human beings. Clin Pharmacol Ther 64:160–7
   PubMed Web of Science ®Google Scholar
• Turpeinen M, Korhonen LE, Tolonen A, et al. (2006). Cytochrome P450 (CYP) inhibition screening: comparison of three tests. Eur J pharm Sci Official J Eur Federation Pharm Sci 29:130–8
   PubMed Web of Science ®Google Scholar
• van Agtmael MA, Cheng-Qi S, Qing JX, et al. (1999a). Multiple dose pharmacokinetics of artemether in Chinese patients with uncomplicated falciparum malaria. Int J Antimicrob Agents 12:151–8
   PubMedGoogle Scholar
• van Agtmael MA, Eggelte TA, van Boxtel CJ. (1999b). Artemisinin drugs in the treatment of malaria: from medicinal herb to registered medication. Trends Pharmacol Sci 20:199–205
   PubMed Web of Science ®Google Scholar
• White NJ, van Vugt M, Ezzet F. (1999). Clinical pharmacokinetics and pharmacodynamics and pharmacodynamics of artemether-lumefantrine. Clin Pharmacokinet 37:105–25
   PubMed Web of Science ®Google Scholar
• WHO (World Health Organization). (2010). Guidelines for the treatment of malaria, 2nd ed. Geneva, Switzerland: World Health Organization
   Google Scholar
• Xing J, Kirby BJ, Whittington D, et al. (2012). Evaluation of P450 inhibition and induction by artemisinin antimalarials in human liver microsomes and primary human hepatocytes. Drug Metab Dispos Biol Fate Chem 40:1757–64
   PubMed Web of Science ®Google Scholar
• Zanger UM, Turpeinen M, Klein K, Schwab M. (2008). Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Anal Bioanal Chem 392:1093–108
   PubMed Web of Science ®Google Scholar